Newsroom

Verantos Announces Breakthrough in Non-alcoholic Steatohepatitis Real-world Evidence

Press Releases

Verantos, the market leader in high-validity real-world evidence generation, announced a significant step forward in applying advanced real-world evidence approaches to non-alcoholic steatohepatitis (NASH), achieving phenotyping accuracy exceeding 90%.

Read at the original outlet
All news
Get started

Ready to advance your evidence program?

Speak with our team about how the Verantos pharmacoepidemiology stack can accelerate your timeline.